PE20120863A1 - 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma que elevan el colesterol hdl - Google Patents

5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma que elevan el colesterol hdl

Info

Publication number
PE20120863A1
PE20120863A1 PE2012000302A PE2012000302A PE20120863A1 PE 20120863 A1 PE20120863 A1 PE 20120863A1 PE 2012000302 A PE2012000302 A PE 2012000302A PE 2012000302 A PE2012000302 A PE 2012000302A PE 20120863 A1 PE20120863 A1 PE 20120863A1
Authority
PE
Peru
Prior art keywords
trifluor
nicotinamide
dichloro
hydroxy
phenyl
Prior art date
Application number
PE2012000302A
Other languages
English (en)
Spanish (es)
Inventor
Stephan Roever
Matthew Wright
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20120863A1 publication Critical patent/PE20120863A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2012000302A 2009-09-11 2010-09-08 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma que elevan el colesterol hdl PE20120863A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09170097 2009-09-11

Publications (1)

Publication Number Publication Date
PE20120863A1 true PE20120863A1 (es) 2012-07-23

Family

ID=42830122

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000302A PE20120863A1 (es) 2009-09-11 2010-09-08 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma que elevan el colesterol hdl

Country Status (34)

Country Link
US (1) US8227491B2 (https=)
EP (1) EP2475645B1 (https=)
JP (1) JP5604520B2 (https=)
KR (1) KR101382871B1 (https=)
CN (1) CN102639506B (https=)
AR (2) AR078352A1 (https=)
AU (1) AU2010294277B2 (https=)
BR (1) BR112012005511B8 (https=)
CA (1) CA2771493C (https=)
CL (1) CL2012000611A1 (https=)
CO (1) CO6491033A2 (https=)
CR (1) CR20120089A (https=)
CY (1) CY1114377T1 (https=)
DK (1) DK2475645T3 (https=)
EC (1) ECSP12011723A (https=)
ES (1) ES2423821T3 (https=)
HR (1) HRP20130869T1 (https=)
IL (1) IL217920A (https=)
IN (1) IN2012DN00763A (https=)
MA (1) MA33563B1 (https=)
MX (1) MX2012002254A (https=)
MY (1) MY161103A (https=)
NZ (1) NZ597514A (https=)
PE (1) PE20120863A1 (https=)
PL (1) PL2475645T3 (https=)
PT (1) PT2475645E (https=)
RS (1) RS52987B (https=)
RU (1) RU2541475C2 (https=)
SG (1) SG179035A1 (https=)
SI (1) SI2475645T1 (https=)
TW (1) TWI412363B (https=)
UA (1) UA107088C2 (https=)
WO (1) WO2011029827A1 (https=)
ZA (1) ZA201201599B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) * 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
WO2014180741A1 (en) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7
US20200085810A1 (en) 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
US11814354B2 (en) * 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
RU2404164C2 (ru) 2005-04-06 2010-11-20 Ф.Хоффманн-Ля Рош Аг Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
KR101107896B1 (ko) 2006-10-04 2012-01-25 에프. 호프만-라 로슈 아게 고 밀도 지단백질(hdl)-콜레스테롤 상승제로서 3-피리딘카복스아마이드 및 2-피라진카복스아마이드 유도체

Also Published As

Publication number Publication date
ES2423821T3 (es) 2013-09-24
HK1172021A1 (en) 2013-04-12
SI2475645T1 (sl) 2013-10-30
PL2475645T3 (pl) 2013-12-31
IL217920A (en) 2015-11-30
AR078352A1 (es) 2011-11-02
CO6491033A2 (es) 2012-07-31
AU2010294277B2 (en) 2015-07-09
CL2012000611A1 (es) 2012-09-07
NZ597514A (en) 2013-10-25
SG179035A1 (en) 2012-04-27
RU2541475C2 (ru) 2015-02-20
RS52987B (sr) 2014-02-28
KR101382871B1 (ko) 2014-04-08
ZA201201599B (en) 2012-11-28
TW201114427A (en) 2011-05-01
CY1114377T1 (el) 2016-08-31
JP5604520B2 (ja) 2014-10-08
IN2012DN00763A (https=) 2015-06-26
BR112012005511A2 (pt) 2016-04-19
ECSP12011723A (es) 2012-04-30
CN102639506A (zh) 2012-08-15
CN102639506B (zh) 2014-09-03
DK2475645T3 (da) 2013-07-22
IL217920A0 (en) 2012-03-29
BR112012005511B1 (pt) 2021-03-02
KR20120048040A (ko) 2012-05-14
HRP20130869T1 (hr) 2013-10-25
CR20120089A (es) 2012-03-22
EP2475645B1 (en) 2013-07-03
AR114032A2 (es) 2020-07-15
WO2011029827A1 (en) 2011-03-17
MY161103A (en) 2017-04-14
UA107088C2 (xx) 2014-11-25
MA33563B1 (fr) 2012-09-01
JP2013504534A (ja) 2013-02-07
CA2771493C (en) 2017-08-29
PT2475645E (pt) 2013-08-05
MX2012002254A (es) 2012-03-16
RU2012113924A (ru) 2013-10-20
EP2475645A1 (en) 2012-07-18
AU2010294277A1 (en) 2012-02-09
US8227491B2 (en) 2012-07-24
TWI412363B (zh) 2013-10-21
US20110065759A1 (en) 2011-03-17
CA2771493A1 (en) 2011-03-17
BR112012005511B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
PE20120863A1 (es) 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma que elevan el colesterol hdl
PE20140065A1 (es) Sal(es) de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico y procesos para su elaboracion
CL2011002745A1 (es) Compuestos derivados de acidos grasos poliinsaturados; metodo de preparacion; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de trastornos cardiovasculares, metabolicos e inflamatorios, tales como, artritis reumatoide, aterosclerosis, diabetes, dislipidemia, entre otras.
ECSP13012770A (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
EA201590653A1 (ru) Терапевтическое средство при дислипидемии
PE20211544A1 (es) Derivados de pirimidiniloxi benceno como herbicidas
UY32848A (es) Compuestos heterocíclicos de oxima
ECSP11010830A (es) Derivados de heteroarilo como inhibidores de dgat1
EA200702541A1 (ru) Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты
TR201909777T4 (tr) Sübsti̇tüe ki̇nazoli̇nonlara yöneli̇k oral çabuk salimli formülasyonlar
EA201500574A1 (ru) Новые инданилоксидигидробензофуранилуксусные кислоты
MA37886B1 (fr) Nouvelles pyridinones bicycliques
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
CY1123456T1 (el) Μεθοδος παρασκευης οπτικως καθαρων και προαιρετικως υποκατεστημενων παραγωγων 2-(1-υδροξυ-αλκυλ)-χρωμεν-4-ονης και χρηση αυτων στην παρασκευη φαρμακευτικων ουσιων
ECSP10010433A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas
CL2013001600A1 (es) Compuestos derivados de acidos 1-bencilcicloalquilcarboxilicos sustituidos; procedimiento de preparacion de dichos compuestos; medicamento que los contiene; y su uso para el tratamiento y/o la prevencion de insuficiencia cardiaca, angina pectoris, hipertonia, afecciones tromboembolicas, insuficiencia renal, entre otras.
CL2012000937A1 (es) Compuestos heterociclicos espiro derivados de ciclohexano, inhibidores de hsl; procedimiento de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de diabetes, sindrome metabolico, dislipidemia, aterosclerosis u obesidad.
CL2016001023A1 (es) Compuesto n-(1-(4-(2-(4-cloro-2,6-dimetilpirimidin-5-il)etil)piperidin-1-il)-1-oxopropan-2-il)ciclopropanocarboxamida, estereoisomero, inhibidores de grelina o-aciltransferasa (goat); composición farmaceutica; y uso para reducir la ganancia de peso y para tratar la diabetes tipo 2.
BR112014003963A2 (pt) compostos e composições como inibidores de quinase c-kit
CL2008000089A1 (es) Compuestos derivados de 2,4-pirimidinona condensada con un heterociclo, inhibidores de pde-4; composicion farmaceutica; combinacion farmaceutica; procedimiento de preparacion de los compuestos, utiles para tratar trastornos inmunes e inflamatorios.
CL2016001172A1 (es) Nuevos inhibidores de dgat2.
CL2014000441A1 (es) Una entidad quimica que comprende el compuesto sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo; inhibidor de la activacion de la enzima nedd-8; forma cristalina i; profarmaco del compuesto; composicion farmaceutica; un metodo para tratar el cancer.
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
AU2014362144A2 (en) 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative

Legal Events

Date Code Title Description
FG Grant, registration